Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A
Phase of Trial: Phase III
Latest Information Update: 23 Sep 2016
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms PATHFINDER 3
- Sponsors Novo Nordisk
- 07 Jun 2017 Biomarkers information updated
- 08 Dec 2015 Results (n=16) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
- 11 Sep 2014 Planned number of patients changed from 18 to 43 as reported by ClinicalTrials.gov record.